| Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the treatment of rare genetic diseases of obesity, which are characterized by early-onset, severe obesity and an insatiable hunger or hyperphagia. Co.'s main product candidate is IMCIVREE (setmelanotide), a melanocortin-4 receptor, agonist for the treatment of rare genetic diseases of obesity. IMCIVREE has been approved by the U.S. Food and Drug Administration for chronic weight management in adult and pediatric patients six years of age and older with obesity due to proopiomelanocortin, proprotein convertase subtilisin/kexin type 1, leptin receptor, deficiency confirmed by genetic testing. The RYTM stock yearly return is shown above.
The yearly return on the RYTM stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the RYTM annual return calculation with any dividends reinvested as applicable (on ex-dates).